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Seoul, Republic of KoreaObjectives This study sought to evaluate the association between newly revealed abnormal ankle-
brachial index (ABI) and clinical outcomes in patients with signiﬁcant coronary artery stenosis.
Background Little is known about the prevalence and clinical implications of ABI in patients with no
claudication or previous history of peripheral artery disease who undergo diagnostic coronary
angiography.
Methods Between January 1, 2006, and December 31, 2009, ABI was evaluated in 2,543 consecutive
patients with no clinical history of claudication or peripheral artery disease who underwent diagnostic
coronary angiography. Abnormal ABI was deﬁned as 0.9 or 1.4. The primary endpoint was the
composite of death, myocardial infarction, and stroke over 3 years.
Results Of the 2,543 patients, 390 (15.3%) had abnormal ABI. Of the 2,424 patients with at least
1 signiﬁcant stenosis (50%) in a major epicardial coronary artery, 385 (15.9%) had abnormal ABI,
including 348 (14.4%) with ABI 0.9 and 37 (1.5%) with ABI 1.4. During a median follow-up of
986 days, the 3-year major adverse event rate was signiﬁcantly higher in patients with abnormal than
normal ABI (15.7% vs. 3.3%, p < 0.001). After multivariate analysis, abnormal ABI was identiﬁed as
a predictor of primary endpoint (hazard ratio [HR]: 1.87; 95% conﬁdence interval [CI]: 1.23 to 2.84;
p ¼ 0.004). After adjustment by propensity-score matching, abnormal ABI could predict adverse
clinical events in patients with established coronary artery disease (HR: 2.40; 95% CI: 1.41 to 4.10;
p ¼ 0.001).
Conclusions The prevalence of newly revealed abnormal, asymptomatic ABI among patients who
have signiﬁcant CAD on coronary angiography was 15.9%. The presence of abnormal ABI was
associated with a higher incidence of adverse clinical outcomes over 3 years. (J Am Coll Cardiol Intv
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1304The ankle-brachial index (ABI), the ratio of systolic blood
pressure measured at the ankle to systolic blood pressure
measured at the brachial artery, is used in the noninvasive
diagnosis of lower-extremity peripheral artery disease
(PAD). Individuals with an abnormal ABI, 0.90 or 1.40,
should be considered at increased risk for lower extremity
PAD, independent of symptoms and other cardiovascular
events (1–5). Both individuals in the general population
and patients with established cardiovascular disease who
have an abnormal ABI are at higher risk of adverse events
than those with normal ABI (6–8). More than 50% ofSee page 1314individuals with PAD are unaware of their disease due to
atypical, vague, or nonspeciﬁc symptoms (9). Little is known
about the actual incidence and clinical implications of newly
revealed abnormal ABI in patients who undergo coronaryAbbreviations
and Acronyms
ABI = ankle-brachial index
CAD = coronary artery
disease
CI = conﬁdence interval
DP = dorsalis pedis
HR = hazard ratio
MI = myocardial infarction
PAD = peripheral artery
disease
PT = posterior tibial
RR = repeat revascularizationangiography. We investigated
whether an abnormal ABI was
an independent risk factor for
atherosclerotic events in patients
with signiﬁcant coronary artery
disease (CAD).
Methods
Study population. Between Jan-
uary 2006 and December 2009,
eligible patients with no clinical
history or previous evaluation of
PAD who underwent diagnostic
coronary angiography were pro-
spectively enrolled in the AsanABI Registry at Asan Medical Center, Seoul, Republic of
Korea. All patients who were admitted for coronary angi-
ography were recommended to undergo an ABI test during
hospitalization. Patients who have never been evaluated for
existence of PAD using the ABI test or managed for PAD
were enrolled, after detailed review of all available medical
records. Those patients were deﬁned as having asymptom-
atic status, which means no clinical history of claudication
was conﬁrmed by the dedicated claudication questionnaire
(10). Coronary angiography was recommended for these
patients on the basis of the results of noninvasive stress tests
(i.e., an exercise treadmill test or a thallium radionuclide
scan), showing inducible ischemia (with or without ischemic
chest pain) or a high probability of ischemic symptoms.
Signiﬁcant stenosis on coronary angiography was deﬁned as
>50% stenosis of an epicardial coronary artery. Treatment of
signiﬁcant stenosis was on the basis of lesion severity,
morphology, comorbidities, clinical characteristics, and
preference. Patients with >50% stenosis and non-ischemic-producing lesions were managed with medical therapy if
functional assessment by fractional ﬂow reserve or nonin-
vasive stress tests such as the treadmill test or myocardial
perfusion imaging was negative. All enrolled patients
provided written informed consent, and the ethics
committee of the Asan Medical Center approved the design
of this study and allowed the use of clinical data.
Data collection and follow-up. Clinical, angiographic,
procedural or operative, and outcome data were collected
with the use of a dedicated Internet-based reporting system.
For validation of complete follow-up data, information
about vital status or clinical event was obtained through
February 28, 2013, from the National Population Registry of
the Korea National Statistical Ofﬁce using a unique personal
identiﬁcation number. Patients were re-examined after 3, 6,
9, and 12 months and semiannually thereafter by ofﬁce visit
or telephone contact. To ensure accurate assessment of
clinical endpoints, additional information was obtained from
visits or telephone contacts with living patients or family
members and from medical records obtained from other
hospitals, as necessary.
Measurement of ABI. The ABI for each leg was measured as
described elsewhere (11) using a Doppler ultrasound device
(Nicolet VasoGuard, Viasys Healthcare, Conshohocken,
Pennsylvania). The sequence of limb pressure measurements
consisted of the ﬁrst arm, the ﬁrst posterior tibial (PT)
artery, the ﬁrst dorsalis pedis (DP) artery, the second PT
artery, the second DP artery, and the second arm. Each
pressure was measured twice, and the average for each was
used in the calculations. The ABI of each leg was calculated
by dividing the PT or DP pressure, whichever was higher, by
the systolic blood pressure for the right or left arm, which-
ever was higher. The ABI selected was the lower of the
values for the left and right legs. If the ABI was found to be
between 0.80 and 1.00, measurements were repeated with
the same principles.
Deﬁnition of abnormal ABI. The ABI threshold most
commonly used is 0.90, which is based on studies showing
that this threshold has about 80% sensitivity and >90%
speciﬁcity to detect PAD when compared with angiography
(12–14). Also, high ABI could predict the incidence of
PAD from 60% to 80% (15,16). In addition to low ABI
(0.90), high ABI (>1.40) may be associated with increased
mortality and other adverse events (2,17). Abnormal ABI
was therefore deﬁned as 0.9 or 1.4.
Endpoints. The primary endpoint of this study was the
composite of death, myocardial infarction (MI), and stroke.
Secondary endpoints were each clinical outcome (death, MI,
or stroke) and repeat revascularization (RR). All events were
on the basis of clinical diagnoses by each patient’s physician
and were centrally adjudicated by an independent group of
clinicians. Death was deﬁned as death from any cause. MI
during follow-up was deﬁned as an increase in cardiac
biomarkers, with at least 1 value above the 99th percentile
Table 1. Baseline Clinical Characteristics of the Overall Population and of
Patients With Abnormal and Normal ABI
Overall
(n ¼ 2,424)
Abnormal ABI
(n ¼ 385)
Normal ABI
(n ¼ 2,039) p Value
Demographic characteristics
Age, yrs 62.9  9.1 66.5  8.5 62.2  9.1 <0.001
Male 1,779 (73.4) 317 (82.3) 1,462 (71.7) <0.001
Cardiac or co-existing conditions
Diabetes mellitus 1,401 (57.8) 246 (63.9) 1,155 (56.6) 0.008
Hypertension 1,644 (67.8) 308 (80.0) 1,336 (65.5) <0.001
Hyperlipidemia 2,001 (82.5) 284 (73.8) 1,717 (84.2) <0.001
Current smoker 631 (26.0) 129 (33.5) 502 (24.6) <0.001
Previous stroke 261 (10.8) 91 (23.6) 170 (8.3) <0.001
Previous PCI 549 (22.6) 103 (26.8) 446 (21.9) 0.036
Previous CABG 91 (3.8) 22 (5.7) 69 (3.4) 0.023
Previous MI 192 (7.9) 38 (9.9) 154 (7.6) 0.122
Renal failure 156 (6.4) 70 (18.2) 86 (4.2) <0.001
LMCA disease 339 (14.0) 64 (16.6) 275 (13.5) 0.108
Multivessel disease 1,496 (61.7) 289 (75.1) 1,207 (59.2) <0.001
Ejection fraction, % 58.5  9.1 55.6  10.9 59.2  8.5 <0.001
Heart failure,
EF < 40%
84 (5.6) 32 (11.2) 52 (4.3) <0.001
Coronary revascularization 1,910 (78.8) 291 (79.0) 1,619 (79.4) 0.103
PCI 1,518 (62.6) 192 (49.9) 1,326 (65.0) <0.001
CABG 392 (16.2) 99 (29.1) 293 (14.4) <0.001
Clinical indication 0.008
Silent/stable angina 1,646 (67.9) 239 (62.1) 1,407 (69.0)
Unstable angina 626 (25.8) 111 (28.8) 515 (25.3)
NSTEMI 97 (4.0) 24 (6.2) 73 (3.6)
STEMI 55 (2.3) 11 (2.9) 44 (2.2)
Medications
Aspirin 2,118 (87.4) 323 (84.2) 1,794 (88.0) 0.044
Clopidogrel 1,596 (65.8) 234 (608) 1,323 (66.8) 0.022
Cilostazol 210 (8.7) 64 (16.6) 146 (7.2) <0.001
Statin 1,872 (77.2) 252 (65.5) 1,620 (79.5) <0.001
ACEI/ARB 935 (38.6) 172 (44.7) 763 (37.4) 0.008
Beta-blocker 1,281 (52.8) 181 (47.0) 1,100 (53.9) 0.014
CCB 1,812 (74.8) 265 (68.8) 1,547 (75.9) 0.002
Nitrate 1,356 (55.9) 209 (54.3) 1,147 (56.3) 0.501
Values are mean  SD or n (%).
ABI ¼ ankle-brachial index; ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angio-
tensin receptor blocker; CABG ¼ coronary artery bypass graft; CCB ¼ calcium channel blocker;
EF ¼ ejection fraction; LMCA ¼ left main coronary artery; MI ¼ myocardial infarction;
NSTEMI ¼ non–ST-segment elevation myocardial infarction; PCI ¼ percutaneous coronary
intervention; STEMI ¼ ST-segment elevation myocardial infarction.
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1305and with at least 1 of the following: 1) symptoms of
ischemia; 2) new or presumed new signiﬁcant ST-segment–
T-wave changes or new left bundle branch block; 3) devel-
opment of pathological Q waves on an electrocardiogram;
4) imaging evidence of new loss of viable myocardium or
new regional wall motion abnormality; or 5) identiﬁcation of
an intracoronary thrombus by angiography or autopsy (18).
Stroke, indicated by the rapid onset of a focal or global
neurological deﬁcit with signs or symptoms, was conﬁrmed
by a neurologist on the basis of neuroimaging results (19).RR was deﬁned as any reintervention using percutaneous
coronary intervention or coronary artery bypass graft of a de
novo and/or restenotic lesion that occurred after completion
of the planned current index procedure. All events were
adjudicated by an independent clinical events committee.
Statistical analysis. All data analyses were performed using
R software (version 2.10.1, R Foundation for Statistical
Computing, Vienna, Austria) and SAS software (version
9.1, SAS Institute, Cary, North Carolina). Patient demo-
graphic characteristics, cardiac or co-existing conditions,
and medication information were compared using Student
t tests for continuous variables and chi-square or Fisher
exact test for categorical variables. Survival curves according
to ABI were constructed with Kaplan-Meier estimates and
compared by the log-rank test. To estimate the effect, we
also performed the univariate Cox proportional hazards
model. Regarding the primary endpoint of death, MI, and
stroke, we performed univariate and multivariate Cox
regression analysis for the risk factor analysis. All baseline
characteristics in Table 1 were tested and if the p value was
0.1 in univariate analysis, the variables were included in
a multivariate analysis. We obtained the ﬁnal model on the
basis of the backward stepwise method where the least
signiﬁcant variables were discarded 1 by 1 from the full
model. Furthermore, to reduce the effect of potential con-
founding in this observational study, we performed rigorous
adjustment for signiﬁcant differences in the baseline char-
acteristics of patients with the use of propensity-score
matching (20). The details of the propensity-score method,
with the resulting models and their predictive characteristics,
are described in the Online Appendix. After all the propen-
sity-score matches were performed, we compared the baseline
covariates between the 2 groups to check the comparability.
Continuous variables were compared using the paired
Student t test or the Wilcoxon signed-rank test, and cate-
gorical variables were compared using the McNemar test.
Statistical signiﬁcance and the estimated effect of treatment
on outcomes were obtained using Cox regression models,
with robust standard errors that accounted for the clustering
of matched pairs. Among the propensity-matched cohort,
survival curves according to ABI were constructed with
Kaplan-Meier estimates and compared by the log-rank test.
Finally, multivariate binary logistic regression analysis was
used to identify predictors of abnormal ABI. Noncorrelated
variables with p values of <0.05 on univariate analyses were
included in the multivariate analysis, and backward stepwise
variable selection approach was employed. All reported
p values are 2-sided, and p values of <0.05 were considered
statistically signiﬁcant.
Results
Prevalence of abnormal ABI. Between January 2006 and
December 2009, 2,543 consecutive patients with no clinical
Figure 1. Overall Study Proﬁle
Of the 2,543 patients, 390 (15.3%) had abnormal ABI. Of the 2,424 patients with at least one signiﬁcant stenosis (50%) in a major epicardial coronary artery, 385
(15.9%) had abnormal ABI, including 348 (14.4%) with ABI 0.9 and 37 (1.5%) with ABI 1.4.
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1306claudication or previous evaluation of PAD, including ABI,
underwent diagnostic coronary angiography. The study
design is illustrated in Figure 1. When patients were strat-
iﬁed according to the presence of signiﬁcant CAD, of the
2,424 patients with signiﬁcant CAD, 385 (15.9%) hadFigure 2. Distribution of ABI Values
The distribution of ankle-brachial index values in the entire cohort (A) and accordin
infarction; STEMI ¼ ST-segment elevation myocardial infarction.abnormal ABI, including 348 (14.4%) with ABI 0.9 and
37 (1.5%) with ABI 1.4. By contrast, of the 119 patients
without signiﬁcant CAD, only 5 (4.2%) had abnormal ABI
(p < 0.001 compared with the incidence of abnormal ABI in
patients with signiﬁcant CAD), with all having ABI 0.9.g to the clinical situation (B). NSTEMI ¼ non–ST-segment elevation myocardial
Table 2. Baseline Clinical Characteristics of the Propensity Score-
Matched Patients With Abnormal and Normal ABI
Abnormal ABI
(n ¼ 359)
Normal ABI
(n ¼ 359) p Value
Demographic characteristics
Age, yrs 66.1  8.4 66.8  8.3 0.25
Male 291 (81.1) 281 (78.3) 0.40
Cardiac or co-existing conditions
Diabetes mellitus 227 (63.2) 224 (62.4) 0.82
Hypertension 283 (78.8) 282 (78.6) 0.93
Hyperlipidemia 271 (75.5) 266 (74.1) 0.73
Current smoker 118 (32.9) 117 (32.6) 0.94
Previous stroke 74 (20.6) 74 (20.6) 1.00
Previous PCI 96 (26.7) 95 (26.5) 0.93
Previous CABG 19 (5.3) 12 (3.3) 0.27
Previous MI 36 (10.0) 37 (10.3) 0.90
Renal failure 54 (15.0) 47 (13.1) 0.45
LMCA disease 58 (16.2) 57 (15.9) 0.91
Multivessel disease 265 (73.8) 256 (71.3) 0.50
Ejection fraction, % 55.7  10.9 57.3  8.8 0.15
Heart failure, EF <40% 23 (6.4) 12 (5.0) 0.13
Coronary revascularization 285 (79.4) 275 (76.6) 0.40
PCI 184 (51.3) 188 (52.4) 0.82
CABG 101 (28.1) 87 (24.2) 0.27
Clinical indication 0.99
Silent/stable angina 225 (62.7) 224 (62.4)
Unstable angina 104 (29.0) 105 (29.2)
Acute MI 30 (8.4) 30 (8.4)
Medications
Aspirin 302 (84.1) 301 (83.8) 0.92
Clopidogrel 219 (61.0) 219 (61.0) 1.00
Cilostazol 61 (17.0) 24 (6.7) <0.001
Statin 240 (66.9) 250 (69.6) 0.47
ACEI/ARB 155 (43.2) 156 (43.5) 0.94
Beta-blocker 173 (48.2) 182 (50.7) 0.50
CCB 245 (68.2) 258 (71.9) 0.33
Nitrate 195 (54.3) 190 (52.9) 0.76
Values are mean  SD or n (%).
Abbreviations as in Table 1.
Table 3. Predictors of Composite of Death, MI, or Stroke After
Multivariate Cox Proportional Hazard Analysis
Variable
Univariate Multivariate
Hazard
Ratio 95% CI p Value
Hazard
Ratio 95% CI p Value
Age, yrs 1.06 1.04–1.08 <0.001 1.05 1.03–1.07 0.001
Abnormal ABI 3.94 2.77–5.61 <0.001 1.87 1.23–2.84 0.004
Hypertension 1.40 0.94–2.09 0.094
Hyperlipidemia 0.56 0.38–0.83 0.004
Previous stroke 2.66 1.76–4.02 <0.001
Previous CABG 2.94 1.27–4.53 0.007
Renal failure 5.53 3.70–8.30 <0.001 3.43 2.17–5.41 <0.001
Multivessel
disease
1.80 1.16–2.77 0.008
Ejection
fraction, %
0.97 0.95–0.99 <0.001 0.98 0.96–0.99 0.025
Clinical indication 1.50 1.16–1.93 0.002
Aspirin 0.006 0.35–0.84 0.006
ACEI/ARB 1.35 0.95–1.92 0.091
Beta-blocker 0.70 0.49–0.99 0.045
CCB 0.60 0.42–0.87 0.006
CI ¼ conﬁdence interval; other abbreviations as in Table 1.
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1307The prevalence of signiﬁcant CAD was signiﬁcantly higher
among patients with abnormal than normal ABI (98.7% vs.
94.7%, p < 0.001). Among 385 patients with abnormal ABI
who had signiﬁcant CAD, 259 patients (67.3%) were
managed with medical therapy and 126 patients (32.7%)
with revascularization (endovascular therapy, 101 [26.2%]
and bypass surgery, 25 [6.5%]); contrarily, among 5 patients
with abnormal ABI who had no signiﬁcant CAD, 4 patients
were managed with endovascular therapy and 1 with medical
therapy.
Distribution of ABI values. The distribution of ABI values in
the entire cohort were illustrated (Fig. 2A) and provided
according to the clinical situation (Fig. 2B). There were
no signiﬁcant differences in ABI values according toindividual clinical situation (1.08  0.19 in silent or stable
angina, 1.06  0.21 in unstable angina, 1.06  0.26 in
non–ST-segment elevation myocardial infarction and
1.05  0.25 in ST-segment elevation myocardial infarction,
respectively; p value ¼ 0.26).
Patient characteristics. The baseline characteristics of the
study patients who have signiﬁcant CAD, categorized by
their ABI values, are shown in Table 1. In general, the
abnormal ABI group was associated with higher risk proﬁles
than the normal ABI group was. Of the 2,424 patients with
signiﬁcant CAD, 1,973 (81.4%) had coronary revasculari-
zation, as determined by functional assessment of stenotic
lesions.
Propensity-score matching of the entire population with
signiﬁcant CAD yielded 359 matched pairs (Table 2). In
these matched cohorts, there were no signiﬁcant differences
in baseline characteristics between those with normal and
abnormal ABI, except for more frequent use of cilostazol in
patients with abnormal ABI, due to its use in the manage-
ment of PAD.
Clinical outcomes. UNADJUSTED OUTCOMES IN THE ENTIRE
COHORT. The median follow-up duration was 986 days
(interquartile range: 673 to 1,483 days).
During follow-up, 78 patients died, 26 had MI, 45 had
a stroke, and 67 underwent RR due to progressive ongoing
ischemia in previously treated or untreated coronary arteries.
As a result, the primary endpoint of the composite of death,
MI, and stroke occurred in 128 patients. After multivariate
analysis, several risk factors including abnormal ABI (hazard
ratio [HR]: 1.87; 95% conﬁdence interval [CI]: 1.23 to 2.84;
Figure 3. Kaplan-Meier Curves of Outcomes in Entire Cohort Patients With Normal and Abnormal ABI
(A) Outcomes for death, myocardial infarction, and stroke. (B to E) Outcomes for freedom from death (B), myocardial infarction (C), stroke (D), and repeat revas-
cularization (E). Event-free survival rates (at 3 years) were derived from paired Kaplan-Meier curves. ABI ¼ ankle-brachial index.
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1308p ¼ 0.004) were identiﬁed as the predictors of primary
endpoint (age: HR: 1.05; 95% CI: 1.03 to 1.07; p < 0.001;
renal failure: HR: 3.43; 95% CI: 2.17 to 5.41; p < 0.001;
and left ventricle ejection fraction: HR: 0.98; 95% CI: 0.96
to 0.99; p ¼ 0.025) (Table 3).
Those with abnormal ABI had signiﬁcantly higher rates
of the composite of death, MI, and stroke (15.7% vs. 3.3%,
p < 0.001), all-cause death (10.5% vs. 1.8%, p < 0.001), and
stroke (5.9% vs. 1.2%, p < 0.001), over 3 years than did
those with normal ABI (Table 4, Fig. 3).
ADJUSTED OUTCOMES IN THE PROPENSITY-MATCHED COHORT.
Figure 4 and Table 5 show the incidences of clinical
outcomes over 3 years, relative to ABI, in the matchedcohort. Among the 359 matched pairs, the primary endpoint
deﬁned as composite of death, MI, and stroke was signiﬁ-
cantly higher in the abnormal ABI group (HR: 2.40; 95%
CI: 1.41 to 4.10; p ¼ 0.001). Among the secondary
endpoint, stroke (HR: 4.68; 95% CI: 1.59 to 13.76;
p ¼ 0.005) was also signiﬁcantly higher in the abnormal
group than in the normal ABI group. But, the risk of death,
MI, and RR did not differ between those with normal and
abnormal ABI.
Dose-response gradient between ABI values and adverse
events. The risk for death, MI, or stroke at 3-year follow-
up for different levels of ABI compared with a normal ABI
of 0.91 to 1.40 formed a reverse J-shaped curve. For levels
of ABI 0.90, the unadjusted HR increased consistently
Table 4. Incidence of Clinical Outcomes According to ABI in the Entire Cohort
Outcome
Outcome Rates Multivariate Adjusted*
Normal ABI
(n ¼ 2,039)
Abnormal ABI
(n ¼ 385) p Valuey Hazard Ratio (95% CI)* p Value
Primary endpoint
Death, MI, or stroke 53 (3.3) 48 (15.7) <0.001 1.87 (1.23–2.84) 0.004
Secondary endpoint
Death 30 (1.8) 32 (10.5) <0.001 1.71 (0.99–2.94) 0.054
MI 8 (0.5) 7 (2.5) 0.123 1.05 (0.32–3.45) 0.93
Stroke 20 (1.2) 18 (5.9) <0.001 2.86 (1.42–5.77) 0.003
Repeat revascularization 43 (2.8) 10 (4.0) 0.668 0.92 (0.45–1.88) 0.81
Values are the number of events (estimated cumulative incidence rate based on Kaplan-Meier curve) for 3-year follow-up. *Hazard ratios of
patients having abnormal ABI compared with those having normal ABI were measured using the multivariate backward stepwise Cox propor-
tional hazard models, which included all variables listed in Table 1. yThe p values are based on the log-rank test.
Abbreviations as in Tables 1 and 3.
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1309with decreasing ABI. For an ABI >1.40, the HR also
increased (HR: 3.73; 95% CI: 1.51 to 9.24) (Fig. 5A).
According to the low, normal, and high ABI groups, there
were signiﬁcant differences in 3-year event rates (3.3% in
normal, 10.2% in high, and 16.2% in low ABI groups, log-
rank p value <0.001) (Fig. 5B). Compared with the
normal ABI group, the low ABI group showed signiﬁcant
risk after multivariate Cox proportional hazard analysis
(adjusted HR: 1.59; 95% CI: 1.10 to 2.50; p ¼ 0.047) and
propensity-matched analysis in 331 matched pairs (HR:
1.50; 95% CI: 1.08 to 2.36; p ¼ 0.046). But compared
with the normal ABI group, the high ABI group showed
a higher trend without statistical signiﬁcance in multivar-
iate Cox proportional hazard analysis (adjusted HR: 1.72;
95% CI: 0.65 to 4.54; p ¼ 0.27) (Fig. 5C).
Also, we classiﬁed 3 groups of low ABI according to the
ABI values using 0.60 and 0.76 as cutoff points. Finally,
we analyzed the total 5-group cohort as low tertile (0.60,
n ¼ 117), middle tertile (>0.60 and 0.76, n ¼ 119),
high tertile (>0.76 and 0.90, n ¼ 112) in the low ABI
group, normal ABI group (>0.90 and 1.40, n ¼ 2,039),
and high ABI (>1.40, n ¼ 37). The cumulative incidences
of primary endpoint at 3-year follow-up were 26.6%, log-
rank p value <0.001; 13.2%, log-rank p value <0.001;
11.3%, log-rank p value ¼ 0.021; 3.3%, normal ABI as
reference; 10.2%, log-rank p value ¼ 0.002, respectively.
After multivariate Cox proportional hazard analysis, there
were dose-response gradients between ABI values and
adverse events (HR: 2.14; 95% CI: 1.28 to 3.70 in the low
tertile; HR: 1.79; 95% CI: 1.09 to 3.32 in the middle
tertile; HR: 1.13; 95% CI: 0.58 to 2.10 in the high tertile;
HR: 1.65; 95% CI: 0.62 to 4.37 in the high ABI group,
in comparison with normal ABI group as reference)
(Fig. 5D).
Predictors of abnormal ABI. Multivariate analysis showed
that older age, male sex, multivessel CAD, current smoking,hypertension, previous stroke, and renal failure were signif-
icant predictors of abnormal ABI (Table 6).
Discussion
We have shown here that the prevalence of abnormal ABI
among patients who had a signiﬁcant CAD on coronary
angiogramwas 15.9% and that abnormal ABI in patients with
signiﬁcant CAD was associated with higher rates of adverse
clinical outcomes over 3 years. Also, we could see a deﬁnite
dose-response gradient between ABI values and adverse
events. We could not determine whether abnormal ABI is
a marker or cause of adverse outcomes, but our ﬁndings
indicate that abnormal ABI among patients with signiﬁcant
CAD could predict 3-year adverse outcomes in a large
observational cohort, independent of the severity of CAD.
In the present study, we found that patients who had
signiﬁcant CAD with abnormal ABI had higher incidences
of cardiovascular events than those with normal ABI did.
We hypothesize that abnormal ABI could increase risk, even
in high-risk patients. Of the entire cohort, the abnormal
ABI group showed higher adverse clinical events. Also, we
analyzed using propensity-score matching due to the
considerable differences in baseline characteristics between
patients with normal and abnormal ABI. Furthermore,
among propensity-score-matched patients, abnormal ABI
was associated with signiﬁcantly higher risks of 3-year
composite death, MI, and stroke (HR: 2.40), and stroke
(HR: 4.68) compared with normal ABI. Although not
statistically signiﬁcant, patients with abnormal ABI also
were at higher risk for death (HR: 1.78), MI (HR: 5.95),
and RR (HR: 1.96).
The most common ABI threshold for abnormality is
0.90, based on studies showing that this ABI has >90%
sensitivity and speciﬁcity to detect PAD compared with
angiography (12,13). A high ABI (1.4) suggests the
Figure 4. Kaplan-Meier Curves of Outcomes in Propensity-Matched Patients With Normal and Abnormal ABI
Propensity matching of patients in the entire cohort yielded 349 matched pairs. (A) Outcomes for death, myocardial infarction, and stroke. Outcomes for freedom from
death (B), myocardial infarction (C), stroke (D), and repeat revascularization (E). Event-free survival rates (at 3 years) were derived from paired Kaplan-Meier curves.
ABI ¼ ankle-brachial index.
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1310presence of calciﬁed vessels, which may occur in patients with
medical calcinosis, diabetes mellitus, or end-stage renal
disease. Although vascular calciﬁcation could allow PAD to
be detected by ABI, high ABI could predict a 60% to 80%
incidence of PAD (15,16,21). So, we deﬁned abnormal ABI
as 0.9 or 1.4.
Because ABI is associated with higher atherosclerotic risk
factors and the prevalence of vascular disease in other
vascular systems, ABI may be a surrogate marker for
systemic atherosclerosis. A low ABI is associated with
higher rates of cardiovascular risk factors and, therefore,
higher rates of coronary heart disease, stroke, transient
ischemic attack, progressive renal insufﬁciency, and all-causemortality (22–27). These results, however, were derived
primarily from population-based cohort studies that
included patients with existing disease (28–32). Similar to
low ABI, abnormally high ABI has been associated with
higher cardiovascular risk (17,33–36). The MESA (Multi-
Ethnic Study of Atherosclerosis) showed that both high and
low ABI were associated with higher cardiovascular risk in
patients without clinical cardiovascular disease (2,37). The
Strong Heart Study also demonstrated that the adjusted HR
for all-cause mortality and cardiovascular mortality rates
were 1.8 and 2.0, respectively, for high ABI and 1.7 and
2.5, respectively, for low ABI relative to normal ABI (0.9 <
ABI <1.4) (24). Most of these ﬁndings were obtained in
Figure 5. Dose-Response Gradient Between ABI Values and Adverse Events
(A) Hazard ratios for death, myocardial infarction, and stroke at 3-year follow-up according to the ankle-brachial index (ABI) values at baseline. Hazard ratios are not
adjusted for cardiovascular risk factors. (B) Kaplan-Meier curves of death, myocardial infarction, and stroke outcomes according to the ABI values at baseline (low,
normal, and high groups). Event-free survival rates (at 3 years) were derived from paired Kaplan-Meier curves. (C) Adjusted hazard ratios for death, myocardial
infarction, and stroke at 3-year follow-up according to ABI values at baseline (low, normal, and high groups). Hazard ratios are derived from multivariate Cox
proportional hazard analysis. (D) Adjusted hazard ratios for death, myocardial infarction, and stroke at 3-year follow-up according to the ABI at baseline (low, middle,
high tertiles in low, normal, and high groups). Hazard ratios are derived from multivariate Cox proportional hazard analysis.
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1311populations with variable risk proﬁles, making it necessary
to determine whether abnormal ABI would be a risk factor
in individual populations. In addition, abnormal ABI has
been associated with future cardiovascular events in patients
with established cardiovascular disease (6–8,31,38–44),
suggesting that abnormal ABI may independently predict
the risk of vascular events in patients with established
cardiovascular disease. Because traditional risk factors are
frequently present in patients with both high and low ABI,
abnormal ABI may increase not only the prevalence but alsoTable 5. Clinical Outcomes in the Propensity-Matched Coh
Normal ABI (n ¼ 359) Abnorm
Event Rate for
3-Year Follow-Up
Ev
3-Ye
Death/MI/stroke 15 (5.5)
Death 13 (4.9)
MI 1 (0.3)
Stroke 3 (0.9)
Repeat revascularization 5 (1.7)
Values are the number of events (estimated cumulative incidence rate b
patients having abnormal ABI compared with those having normal ABI we
Abbreviations as in Tables 1 and 3.the risk of future cardiovascular events. These ﬁndings,
however, are limited by the ambiguous deﬁnition of PAD,
the relatively small numbers of patients surveyed, and the
lack of adjustment for different characteristics. We therefore
analyzed patients with signiﬁcant coronary stenosis who
were undergoing coronary angiography. On the basis of
updated guidelines, we used universal deﬁnitions of clinical
events and abnormal ABI with standardized measurements
(11,18,19). Finally, to minimize biases, we aggressively
adjusted our patient population using propensity-matchedort According to ABI
al ABI (n ¼ 359)
Hazard Ratio (95% CI)* p Value
ent Rate for
ar Follow-Up
41 (14.2) 2.40 (1.41–4.10) 0.001
25 (8.4) 1.78 (0.98–3.24) 0.059
6 (2.3) 5.95 (0.71–49.52) 0.099
17 (6.0) 4.68 (1.59–13.76) 0.005
10 (4.3) 1.96 (0.73–5.23) 0.178
ased on Kaplan-Meier curve) for 3-year follow-up. *Hazard ratios of
re measured using the Cox proportional hazard models.
Table 6. Predictors of Abnormal ABI
Odds Ratio (95% CI) p Value
Renal failure 4.13 (2.83–6.04) <0.001
Previous stroke 2.43 (1.77–3.33) <0.001
Male 2.00 (1.34–3.00) 0.001
Current smoking 1.83 (1.39–2.41) <0.001
Hypertension 1.74 (1.30–2.32) <0.001
Multivessel disease 1.54 (1.18–2.02) 0.001
Age, yrs 1.06 (1.04–1.07) <0.001
Abbreviations as in Tables 1 and 3.
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1312analysis (45,46). Matching according to propensity score
eliminates a greater proportion of baseline differences
between 2 groups than stratiﬁcation or adjustment for
covariates does (47). Our data are therefore an updated
analysis of abnormal ABI and cardiovascular events in
patients with established CAD.
Study limitations. Our evaluation of observational cohort
data, not randomized patients, is a major limitation.
Moreover, our deﬁnition of “newly revealed ABI” may be
faulty, because the initial evaluation with ABI may be
arbitrary and may depend on the characteristics of the
physician or patient. This may lead to an unintended
under- or overestimation of the prevalence of ABI. We
attempted to minimize any errors in estimation of incidence
by standardizing inclusion criteria using available resources
such as a detailed review of all available medical records and
questionnaire with patients and their families (10). From an
analytical standpoint, our ﬁndings are subject to selection
bias and confounding with respect to the patients’ symptoms
and history of previous evaluation. Using propensity-score
matching, the rigorous adjustment was performed to reduce
unexpected bias. It is difﬁcult to perform randomized trials
to evaluate the impact of abnormal ABI for future clinical
outcomes, but our analysis should be meaningful.Conclusions
The prevalence of newly revealed, asymptomatic abnormal
ABI among patients who have signiﬁcant CAD on coronary
angiography was 15.9%. The presence of abnormal ABI was
independently associated with a higher incidence of adverse
clinical outcomes over 3 years. Measurement of ABI could
provide an important insight into the prognosis of patients
with signiﬁcant CAD.
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